Glenn F. Pierce

23.6k citations

222 papers · 15.8k indexed · 7 hit papers · h-index 69

Rehabilitation top 0.05%
- Wound Healing and Treatments 33
Hematology top 0.1%
- Hemophilia Treatment and Research 97
- Platelet Disorders and Treatments 43
- Blood Coagulation and Thrombosis Mechanisms 31
Urology top 0.1%
Genetics top 0.2%
- Virus-based gene therapy research 53
Genetics top 0.5%
- Virus-based gene therapy research 53
Oncology
- CAR-T cell therapy research 31
Molecular Biology
- Viral Infectious Diseases and Gene Expression in Insects 17
- RNA Interference and Gene Delivery 16

Co-authors: Thomas A. Mustoe Thomas F. Deuel Arlen Thomason Haiyan Jiang J E Tarpley Jürg M. Sommer Michael B. Sporn Margaret V. Ragni
Cited by: Rehabilitation Hematology Urology
Journals: Science (1 paper)New England Journal of Medicine (3 papers)Proceedings of the National Academy of Sciences (3 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Glenn F. Pierce

212 papers receiving 15.2k citations

Hit Papers

7 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2020 New England Journal of Medicine
2020 Haemophilia
2017 New England Journal of Medicine
2007 Nature Medicine
1991 Journal of Cellular Biochemistry
1989 The Journal of Cell Biology
1987 Science

Peers

Countries citing papers authored by Glenn F. Pierce

Since Specialization

Citations

This map shows the geographic impact of Glenn F. Pierce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glenn F. Pierce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glenn F. Pierce more than expected).

Fields of papers citing papers by Glenn F. Pierce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Glenn F. Pierce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glenn F. Pierce. The network helps show where Glenn F. Pierce may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Glenn F. Pierce, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Glenn F. Pierce Line = papers co-authored together Glenn F. Pierce links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Therapeutic innovations in hemophilia: the essential role of a positive reinvestment cycle Blood Advances ·Cédric Hermans,Glenn F. Pierce	2025	0
2	Global prophylaxis trends in hemophilia: a macroeconomic analysis and its association with world development indicators Expert Review of Hematology ·M. Joseph John,Jeffrey S. Stonebraker,Aikaj Jindal,Ellia Tootoonchian,Glenn F. Pierce,Emna Gouider,Arihant Jain,Donna Coffin	2024	0
3	The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of Hemophilia Journal of Thrombosis and Haemostasis ·Vincenzo La Mura,Massimo Colombo,Graham R. Foster,Paolo Angeli,Wolfgang Miesbach,Robert Klamroth,Glenn F. Pierce,Brian O’Mahony,Ming Y Lim,Virginia Hernández–Gea,Michael Makris,Flora Peyvandi	2024	6
4	Hemophilia gene therapy: first, do no harm Journal of Thrombosis and Haemostasis ·Leonard A. Valentino,Radosław Kaczmarek,Glenn F. Pierce,Declan Noone,Brian O’Mahony,David Page,Dawn Rotellini,Mark W. Skinner	2023	11
5	Reported prevalence of von Willebrand disease worldwide in relation to income classification Haemophilia ·Jeffrey S. Stonebraker,Alfonso Iorio,Michelle Lavin,Suely Meireles Rezende,Alok Srivastava,Glenn F. Pierce,Donna Coffin,Ellia Tootoonchian,Michael Makris	2023	12
6	The underevaluated impacts of the therapeutic revolution of hemophilia on women and girls Journal of Thrombosis and Haemostasis ·Cédric Hermans,Evelien Krumb,Dawn Rotellini,Glenn F. Pierce	2023	7
7	Two gene therapies for hemophilia available: Now what? Molecular Therapy ·Glenn F. Pierce,Roland W. Herzog	2023	12
8	Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States Journal of Thrombosis and Haemostasis ·Jill M. Johnsen,Shelley Nakaya Fletcher,Angela Dove,Haley McCracken,Beth Martin,Martin Kircher,Neil C. Josephson,Jay Shendure,Sarah Ruuska,Leonard A. Valentino,Glenn F. Pierce,Crystal Watson,Dunlei Cheng,Michael Recht,Barbara A. Konkle	2022	16
9	Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years The Lancet Haematology ·Glenn F. Pierce,Megan Adediran,Saliou Diop,Amy L. Dunn,Magdy El Ekiaby,Radosław Kaczmarek,Barbara A. Konkle,Steven W. Pipe,Mark W. Skinner,Leonard A. Valentino,Fiona Robinson,Georgios Ampartzidis,Jayson Martin,Assad Haffar	2022	38
10	Sixth Åland Island Conference on von Willebrand disease Haemophilia ·Erik Berntorp,Sonata Šaulytė Trakymienė,Augusto B. Federici,Katharina Holstein,Fernando F. Corrales‐Medina,Glenn F. Pierce,Alok Srivastava,M. von Depka Prondzinski,Jill M. Johnsen,Irena Zupan,Susan Halimeh,Vuokko Nummi,Jonathan Roberts	2022	4
11	Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders Haemophilia ·Radosław Kaczmarek,Magdy El Ekiaby,Daniel P. Hart,Cédric Hermans,Michael Makris,Declan Noone,Brian O’Mahony,David Page,Flora Peyvandi,Steven W. Pipe,Thomas Sannié,Uwe Schlenkrich,Mark W. Skinner,Alok Srivastava,Amanda Bok,Glenn F. Pierce	2021	6
12	The World Federation of Hemophilia Annual Global Survey 1999‐2018 Haemophilia ·Jeffrey S. Stonebraker,Paula Bolton‐Maggs,Mark Brooker,Bruce L. Evatt,Alfonso Iorio,Michael Makris,Brian O’Mahony,Mark W. Skinner,Donna Coffin,Glenn F. Pierce,Ellia Tootoonchian	2020	74
13	Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor? Haemophilia ·Glenn F. Pierce,Radosław Kaczmarek,Declan Noone,Brian O’Mahony,David Page,Mark W. Skinner	2020	19
14	Reimbursing the value of gene therapy care in an era of uncertainty Haemophilia ·Declan Noone,Donna Coffin,Glenn F. Pierce	2020	9
15	The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world Haemophilia ·Glenn F. Pierce,Donna Coffin	2019	35
16	First‐year results of an expanded humanitarian aid programme for haemophilia in resource‐constrained countries Haemophilia ·Glenn F. Pierce,Assad Haffar,Georgios Ampartzidis,Flora Peyvandi,Saliou Diop,Magdy El Ekiaby,H. Marijke van den Berg	2018	29
17	Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients Blood ·Jerry S. Powell,Neil C. Josephson,Doris Quon,Margaret V. Ragni,Gregory Cheng,Ella Li,Haiyan Jiang,Lian Li,Jennifer Dumont,Jaya Goyal,Xin Zhang,Jürg M. Sommer,Justin T. McCue,Margaret Barbetti,Alvin Luk,Glenn F. Pierce	2012	171
18	Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs Blood ·Jennifer Dumont,Tongyao Liu,Susan C. Low,Xin Zhang,George D. Kamphaus,Paul Sakorafas,Cara Fraley,Douglas Drager,Thomas J. Reidy,Justin T. McCue,Helen Franck,Elizabeth P. Merricks,Timothy C. Nichols,Alan J. Bitonti,Glenn F. Pierce,Haiyan Jiang	2012	115
19	Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment Blood ·Baisong Mei,Clark Q. Pan,Haiyan Jiang,Hendri Tjandra,Jonathan Strauss,Yaoqi Chen,Tongyao Liu,Xin Zhang,Joanne C. Severs,Jim Newgren,Jian‐Min Chen,Jian-Ming Gu,Babu Subramanyam,Michael A. Fournel,Glenn F. Pierce,John E. Murphy	2010	176
20	Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy Blood ·Haiyan Jiang,Linda B. Couto,Susannah Patarroyo‐White,Tongyao Liu,Dea Nagy,Joseph Vargas,Shangzhen Zhou,Ciaran D. Scallan,Jürg M. Sommer,Sharmila Vijay,Federico Mingozzi,Katherine A. High,Glenn F. Pierce	2006	276

About Glenn F. Pierce

Glenn F. Pierce is a scholar working on Hematology, Rehabilitation and Urology, having authored 222 papers that have together received 15.8k indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (97 papers), Virus-based gene therapy research (53 papers), Platelet Disorders and Treatments (43 papers), Wound Healing and Treatments (33 papers), Blood Coagulation and Thrombosis Mechanisms (31 papers), CAR-T cell therapy research (31 papers), Viral Infectious Diseases and Gene Expression in Insects (17 papers) and RNA Interference and Gene Delivery (16 papers). The work is most often cited by research in Rehabilitation (2.7k citations), Hematology (4.1k citations) and Urology (1.5k citations). Glenn F. Pierce has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Thomas A. Mustoe, Thomas F. Deuel, Arlen Thomason, Haiyan Jiang, J E Tarpley, Jürg M. Sommer, Michael B. Sporn, Margaret V. Ragni, Shangzhen Zhou and John Pasi. Their work appears in journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact